Intellia Therapeutics (NTLA) Earnings Date, Estimates & Call Transcripts $9.60 +0.02 (+0.21%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$9.30 -0.31 (-3.18%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Intellia Therapeutics Earnings Summary Intellia Therapeutics issued Q1 2025 earnings on May 8, 2025, reporting an EPS of -$1.10, which topped analysts' consensus estimates of -$1.26 by $0.16. Quarterly revenue fell 42.6% year-over-year to $16.63 million, above analyst estimates of $11.39 million. With a trailing EPS of -$5.23, Intellia Therapeutics' earnings are expected to grow next year, from ($5.07) to ($5.00) per share. Upcoming Q2 Earnings DateAug. 14Before Market OpensEstimatedConsensus EPS (May. 8) -$1.26 Actual EPS (May. 8) -$1.10 Beat By $0.16 Actual Revenue (May. 8) $16.63MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)NTLA Upcoming EarningsIntellia Therapeutics' next earnings date is estimated for Thursday, August 14, 2025, based on past reporting schedules. Powered by Get Intellia Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Intellia Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataNTLA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.NTLA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Intellia Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20254-$1.40-$1.38-$1.39Q2 20254-$1.42-$1.08-$1.27Q3 20254-$1.62-$1.17-$1.43Q4 20253-$1.55-$1.18-$1.39 FY 2025 15 -$5.99 -$4.81 -$5.47 Q1 20263-$1.48-$1.12-$1.32Q2 20263-$1.48-$1.22-$1.32Q3 20263-$1.56-$1.28-$1.46Q4 20263-$1.67-$1.17-$1.40 FY 2026 12 -$6.19 -$4.79 -$5.50 Q1 20271-$0.97-$0.97-$0.97 Intellia Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 8/14/2025(Estimated)--------5/8/2025Q1 2025-$1.26-$1.10+$0.16-$1.10$11.39M$16.63M11/7/2024Q3 2024-$1.37-$1.34+$0.03-$1.34$8.28M$9.10M8/8/2024Q2 2024-$1.23-$1.52 -$0.29-$1.10$19.68M$7.00M5/9/2024Q1 2024-$1.35-$1.06+$0.29-$1.00$15.60M$28.94M2/22/2024Q4 2023-$1.47-$1.46+$0.01-$1.46$15.10M-$1.92M11/9/2023Q3 2023-$1.52-$1.38+$0.14-$1.38$12.45M$11.99M8/3/2023Q2 2023-$1.32-$1.40 -$0.08-$1.40$12.08M$13.59M Intellia Therapeutics Earnings - Frequently Asked Questions When is Intellia Therapeutics' earnings date? Intellia Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, August 14th, 2025 based off last year's report dates. Learn more on NTLA's earnings history. Did Intellia Therapeutics beat their earnings estimates last quarter? In the previous quarter, Intellia Therapeutics (NASDAQ:NTLA) reported ($1.10) earnings per share (EPS) to beat the analysts' consensus estimate of ($1.26) by $0.16. Learn more on analysts' earnings estimate vs. NTLA's actual earnings. How can I listen to Intellia Therapeutics' earnings conference call? The conference call for Intellia Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Intellia Therapeutics' conference call transcript? The conference call transcript for Intellia Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded annual revenue of $57.88 million. How much profit does Intellia Therapeutics generate each year? Intellia Therapeutics (NASDAQ:NTLA) has a recorded net income of -$519.02 million. NTLA has generated -$5.23 earnings per share over the last four quarters. What is Intellia Therapeutics' EPS forecast for next year? Intellia Therapeutics' earnings are expected to grow from ($5.07) per share to ($5.00) per share in the next year. More Earnings Resources from MarketBeat Related Companies ACAD Earnings Results MRUS Earnings Results RNA Earnings Results SWTX Earnings Results ACLX Earnings Results RARE Earnings Results PTGX Earnings Results SRRK Earnings Results KYMR Earnings Results VKTX Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Broadcom Slides on Solid Earnings, AI Outlook Still StrongFive Below Pops on Strong Earnings, But Rally May StallRed Robin's Comeback: Q1 Earnings Spark Investor HopesOllie’s Q1 Earnings: The Good, the Bad, and What’s NextBroadcom Earnings Preview: AVGO Stock Near Record HighsUlta’s Beautiful Q1 Earnings Report Points to More Gains Aheade.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal This page (NASDAQ:NTLA) was last updated on 6/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
